細胞番号 : 細胞名
RCB2536 : T24
update : 2024/08/14
|
| 細胞特性(Comment:英) | Human cell line derived from bladder cancer. Transitional cell carcinoma. TKG0443 (Deposited from Tohoku Univ.). |
| 細胞特性(日) | ヒト膀胱癌由来細胞株。Transitional cell carcinoma. TKG0443 (東北大学医用細胞資源センターからの寄託)。 |
| 細胞特性(寄託者記述:英) | |
| 細胞特性(寄託者記述:日) | |
| 使用条件(英) | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| 使用条件(日) | 基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。 |
| 備考(英) | |
| 備考(日) | |
| 提供申込書類(英) |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
| 提供申込書類(日) |
依頼書C-0001.pdf
同意書(非営利学術目的)C-0003.pdf
同意書(営利目的)C-0003p.pdf
|
|
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
|
| 提供手数料 |
手数料とお支払いについてはこちらをご覧ください。 |
|
細胞基本情報
|
|
寄託者 |
Fukuda, Hiroshi
|
| 樹立者 |
Bubenick, J.
|
| 寄託日 |
2007
|
| 元の細胞 |
TKG0443
|
| 動物種 |
_human
< Mammals
|
| 属名 |
Homo
|
| 種名 |
sapiens
|
| 性別 |
Female
|
| 齢 |
81 years
|
| 採取組織 |
bladder
|
| 病名 |
transitional-cell carcinoma
|
| 細胞分類 |
cancer
|
| 入手歴 |
Cell Resource Center for Biomedical Research, Tohoku University（TKG0443）
|
|
細胞寿命 |
infinite
|
| 細胞形態 |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_0554
|
|
細胞培養・検査情報
| |
寄託時情報 |
ロット情報 |
| 培地・試薬情報 |
培地・試薬一覧はこちらをご覧ください。 |
|
培養形態 |
|
Adherent cells
|
| 培地 |
|
MEM + 10% FBS
|
| 抗生物質 |
|
Free
|
|
継代方法 |
|
0.25% Trypsin
|
|
継代密度 |
|
1 : 8 split
|
| 継代・培地交換頻度 |
|
Subculture : 2 times/week
|
| 培養最適温度 |
|
37
℃
|
| 二酸化炭素濃度 |
|
5
%
|
| 凍結培地 |
|
Medium + 10% DMSO
|
| 凍結方法 |
|
Slow freezing
|
| マイコプラズマ/アコレプラズマ |
|
(-)
|
| アイソザイム検査 |
|
LD, NP
|
| 個体識別検査 |
|
OK
|
| 画像情報 |
寄託時情報 | ロット情報 |
|
|
|
| 文献情報 |
Reference(英) |
6件
|
| Reference(日) |
2件
|
| 利用者成果(英) |
9件
|
| 利用者成果(日) |
0件
|
| Reference(英) |
|
190
Bubeník J, Kieler J, Tromholt V, Steven K, Indrová M, Toulcová A.
Activation of killer cells from blood of urinary bladder carcinoma patients by short-term treatment with recombinant interleukin 2
Folia Biol (Praha)
1986
32(3):183-94
PubMed ID: 3488923
|
|
189
Bubeńik J, Kieler J, Perlmann P, Paulie S, Koho H, Christensen B, Dienstbier Z, Koprivová H, Pospísil J, Poucková P.
Monoclonal antibodies against human urinary bladder carcinomas: selectivity and utilization for gamma scintigraphy
Eur J Cancer Clin Oncol
1985
21(6):701-10
PubMed ID: 3894033
DOI: 10.1016/0277-5379(85)90267-6
|
|
191
Bubeník J, Kieler J, Perlmann P, Paulie S, Koho H, Christensen B, Dienstbier Z, Koprivová H, Pospísil J, Novák F.
Tumour localization of radiolabelled monoclonal antibody in mice bearing human urinary bladder (T24) carcinoma xenografts
Folia Biol (Praha)
1985
31(2):176-84
PubMed ID: 3894060
|
|
4680
Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV.
Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue.
Nature
1983
302:33-7
PubMed ID: 6298635
DOI: 10.1038/302033a0
|
|
1173
Bubeník J, Baresová M, Viklický V, Jakoubková J, Sainerová H, Donner J.
Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.
Int J Cancer
1973
11(3):765-73
PubMed ID: 4133950
DOI: 10.1002/ijc.2910110327
|
|
1172
Bubeník J, Perlmann P, Helmstein K, Moberger G.
Cellular and humoral immune responses to human urinary bladder carcinomas.
Int J Cancer
1970
5(3):310-9
PubMed ID: 5452065
DOI: 10.1002/ijc.2910050303
|
| 利用者成果(英) |
|
22359
Fuchizawa H, Ando K, Motoi N, Iizuka T, Inoue M, Mitani K, Sano Y, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y.
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer
Anticancer Res
2024
44(5):1925-1930
PubMed ID: 38677727
DOI: 10.21873/anticanres.16994
|
|
21362
Ando K, Kurashina R, Motoi N, Iizuka T, Inoue M, Maruyama R, Mitani K, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y.
Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.
Biochem Biophys Res Commun
2023
676:165-170
PubMed ID: 37517219
DOI: 10.1016/j.bbrc.2023.07.054
|
|
17640
Kobayashi T, Kishimoto S, Watanabe S, Yoshioka Y, Toyoda T, Ogawa K, Watanabe K, Totsuka Y, Wakabayashi K, Miyoshi N.
Cytotoxic Homo- and Hetero-Dimers of o-toluidine, o-anisidine, and Aniline Formed by In Vitro Metabolism
Chem Res Toxicol
2022
35(9):1625-1630
PubMed ID: 36001821
DOI: 10.1021/acs.chemrestox.2c00226
|
|
20774
Kubota Y, Fujioka Y, Patil A, Takagi Y, Matsubara D, Iijima M, Momose I, Naka R, Nakai K, Noda NN, Takekawa M.
Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer.
Nat Commun
2022
13(1):4063
PubMed ID: 35831322
DOI: 10.1038/s41467-022-31690-w
|
|
16985
Kobayashi T, Toyoda T, Tajima Y, Kishimoto S, Tsunematsu Y, Sato M, Matsushita K, Yamada T, Shimamura Y, Masuda S, Ochiai M, Ogawa K, Watanabe K, Takamura-Enya T, Totsuka Y, Wakabayashi K, Miyoshi N.
o-Anisidine Dimer, 2-Methoxy- N4-(2-methoxyphenyl) Benzene-1,4-diamine, in Rat Urine Associated with Urinary bladder Carcinogenesis
Chem Res Toxicol
2021
34(3):912-919
PubMed ID: 33587850
DOI: 10.1021/acs.chemrestox.0c00536
|
|
13009
Tajima Y, Toyoda T, Hirayama Y, Matsushita K, Yamada T, Ogawa K, Watanabe K, Takamura-Enya T, Totsuka Y, Wakabayashi K, Miyoshi N.
Novel o-Toluidine Metabolite in Rat Urine Associated with Urinary Bladder Carcinogenesis.
Chem Res Toxicol
2020
PubMed ID: 32343562
DOI: 10.1021/acs.chemrestox.0c00098
|
|
13311
Sugiyama T, Ozono S, Miyake H.
Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma.
Anticancer Res
2020
PubMed ID: 33109571
DOI: 10.21873/anticanres.14654
|
|
13329
Matsumura E, Kosuge N, Nakanishi S, Suda T, Sugawa A, Fujimura T, Miyagi R, Yoshimi N, Saito S.
Urine Lactoferrin as a Potential Biomarker Reflecting the Degree of Malignancy in Urothelial Carcinoma of the Bladder.
Tohoku J Exp Med
2020
PubMed ID: 33162487
DOI: 10.1620/tjem.252.225
|
|
14268
Yamashita T, Higashi M, Momose S, Morozumi M, Tamaru JI.
Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer
Int J Oncol
2017
51(2):579-586
PubMed ID: 28714514
DOI: 10.3892/ijo.2017.4031
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト
